A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a research study for people with high blood phosphorus levels who are on dialysis.
This medical condition can cause weakening of the bones and damage other organs. This can
lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat,
and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid
of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often
patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood
phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric
citrate) is safe and effective as a phosphate binder.